There is currently no standardized approach for the treatment of steroid-refractory acute GvHD (SR-aGvHD). 1, 2 Alemtuzumab has been shown to have clinical activity in a number of small prospective and retrospective studies, but optimal doses remain unknown and survival remains poor, with deaths from both GvHD and infection contributing. [3] [4] [5] [6] [7] [8] Critically, very little is known about alemtuzumab's pharmacokinetics and pharmacodynamics in this context, and therefore dosing is empirical, ranging from 10-50 mg in the first week, with or without repeat dosing at 10-30 mg every 1-4 weeks. [3] [4] [5] [6] [7] In order to better define the clinical outcome and develop a rational approach to alemtuzumab dosing in SR-aGvHD, we conducted a phase II clinical study in which we incorporated weekly pharmacokinetics and immunological monitoring.
This study was opened at the Royal Brisbane and Women's Hospital (RBWH), Royal Melbourne Hospital and Westmead Hospital, all in Australia. The primary end point was overall survival at 6 months post alemtuzumab. The secondary end points were aGvHD response, infection rate and incidence of chronic GvHD. The study was approved by the human research ethics committee at the RBWH and registered on the Australian New Zealand Clinical Trials Registry (ACTRN12613000288729). The target enrollment was 16 patients based on a 6-month overall survival of 50% for SR-aGvHD treated with anti-thymoglobulin (ATG)-based therapy at the RBWH. 9 Regrettably, however, the study was closed after the enrollment of four patients as access to alemtuzumab was prevented by a new pharmaceutical supplier within the context of their repurposing development.
SR-aGvHD was defined as progressive GvHD after 3 days, no improvement after 7 days or incomplete response after 14 days of prednisolone at ⩾ 1 mg/kg/day (or equivalent), or recurrence of GvHD grade ⩾ 2 while receiving prednisolone at ⩾ 0.5 mg/kg/day (or equivalent). The GvHD must be biopsy-proven and grade ⩾ 2 per Glucksberg criteria. 10 Patients must be aged 18-69 years old. Exclusion criteria were treatment with other investigational agents, uncontrolled intercurrent illness, including infections, seropositivity for hepatitis B virus, hepatitis C virus or HIV, pregnancy, hypersensitivity to alemtuzumab or similar compounds, and the presence of human anti-mouse antibodies. Alemtuzumab was commenced within 72 h of diagnosis of SR-aGvHD. It was administered IV for 5 consecutive days at 10 mg/day in the first patient and 5 mg/day in subsequent patients. Prednisolone at 2 mg/kg/day (or equivalent) was administered for 7 days then tapered. Patients also received mycophenolate mofetil (MMF) at 15 mg/kg twice daily and etanercept at 0.4 mg/kg (maximum 25 mg) SC twice per week for 4 weeks, then weekly for a further 4 weeks (12 doses in total). Patients on cyclosporin were converted to tacrolimus. Ursodeoxycholic acid and non-absorbable glucocorticoids were allowed in liver and gut GvHD, respectively. Prophylactic antimicrobials consisted of valaciclovir, extended-spectrum azoles (posaconazole or voriconazole) and cotrimoxazole. PCR was performed weekly for CMV and fortnightly for Epstein-Barr virus and human herpesvirus 6.
Complete response (CR) was defined as resolution of all manifestations of aGvHD and partial response (PR) as a reduction in the overall aGvHD grade by ⩾ 1. 10 Plasma alemtuzumab level was measured by flow cytometry using a modification of published methods. 11, 12 In brief, plasma samples were thawed, heat inactivated, and incubated for 40 min at room temperature with peripheral blood mononuclear cells from a buffy coat discard. The cells were washed, incubated for 30 min at room temperature with 10 μg/mL FITC-conjugated goat anti-human IgG Fc domain (Novex, Life Technologies, Frederick, MD, USA) together with CD3-APC.Cy7, CD4-AF700 and CD16-PE (Biolegend, San Diego, CA, USA), washed, fixed with 1% paraformaldehyde and acquired on an LSR Fortessa (BD Biosciences, San Jose, CA, USA). The FITC geometric mean fluorescence intensity gated on CD3 + CD4 + CD16
− cell population was compared with spiked plasma that were similarly frozen, thawed and heat inactivated. Peripheral blood cell subsets were enumerated by the dual platform method. In brief, flow cytometry was performed fresh using a red cell-lysed, non-wash technique. The following Abs were used: CD45-V500, CD56-PE.Cy7, CD20-PE.Cy7, CD14-Pacific Blue, CD3-AF700, CD16-FITC, HLA-DR-APC.Cy7, CD11c-PE.Cy5, CD1c-PE and CD123-PerCP.Cy5.5. Absolute cell counts were derived from counts from the automated hematology analyzer. The study was closed early after the enrollment of four patients, all at the RBWH, because alemtuzumab was no longer accessible. The patients were aged 39-67 years old. Two had skin GvHD (stage 3 skin, overall grade 2) and two had gut GvHD (stage 1 gut, overall grade 2; stage 4 gut, overall grade 4). At day 28, three had a CR and one had a PR. Three patients died: one from opportunistic infection at day 61, and two from recurrent aGvHD at days 97 and 345, the first following initial PR and the second after withdrawal of immune suppression in the setting of disease relapse. One patient is alive at 41 year with chronic GvHD. In view of the depth and duration of T-cell depletion in the first patient, who succumbed to infective complications, the dose of alemtuzumab was reduced from 10 mg/day × 5 days to 5 mg/day × 5 days in subsequent patients. Overall, three out of four patients had significant infective complications. All patients had grade 3 or 4 cytopenia that required MMF cessation or dose reduction.
The limit of detection of alemtuzumab using our methodology was 0.2 mg/mL (Figure 1a) . The mean plasma concentration on day 7 was 17.4 mg/mL (range 10.5-24.0). The level in patient #1 was 13.6 mg/mL, and hence not different from patients receiving half the dose. The half-life of alemtuzumab was 6.3 days and all patients had detectable levels (40.2 mg/mL) at 4 weeks (Figure 1b) . Total T-cell counts fell within the first week and nadir at 0-4/μL (Figure 1c ). T-cell numbers did not begin to recover until after 5-6 weeks and no patient had a T-cell count that was consistently 450/μL in the first 2 months, consistent with the concept that an antibody level as low as 0.1 mg/mL is sufficient to mediate antibody-dependent cell cytotoxicity in vivo. 13 There was also depletion of B cells, but no effect on natural killer cells, monocytes and dendritic cells (Figure 1d ). We also studied three contemporaneous patients with SR-aGvHD who were not on the study (two declined and one could not be enrolled as alemtuzumab was no longer available) and were enrolled on an observational study (HREC/14/QRBW/170). These patients were treated with our unit's standard salvage protocol consisting of horse ATG 15 mg/kg per day for 5 days, together with etanercept +/ − MMF. 9 In contrast to alemtuzumab-treated patients, the degree of T-cell depletion was much less: the nadir T-cell count was 27-57/μL and all patients recovered T-cell counts to 4100/μL within 3 weeks (Figure 1e) .
Alemtuzumab-based combination therapy has clinical activity in SR-aGvHD and results in rapid, profound and prolonged T-cell depletion even at low doses, consistent with the effect of low target cell burden on alemtuzumab pharmacokinetics when used to treat immune pathology. 14, 15 Prospective studies will be required to further define and refine the use of alemtuzumab for this indication, but unfortunately there appears to be little prospect of accessing the drug within appropriate clinical trial settings in the foreseeable future as it is no longer supplied or purchasable for clinical studies although it continues to be available for off-label, off-study use in SR-aGvHD. Our data suggests that total doses of 25 mg or less are adequate and immunologically more potent than ATG-based strategies. Furthermore, given the depth of T-cell depletion, cumulative doses beyond 25 mg are unlikely to improve response rates and likely to increase infective complications. 
